Evaluation of COVID-19 incidence in psoriatic patients receiving Adalimumab

Authors

  • Esmat Davoudi-Monfared Health Management Research Center, Department of Community Medicine, Baqiyatallah University of Medical Sciences
  • Fakhri Allahyari Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Hamideh Molaee Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
  • Javad Nejad Neuroscience Research Center, Baqiyatallah University of Medical Sciences
Abstract:

Background: Adalimumab is a highly human monoclonal antibody that binds to tumor necrosis factor, a key proinflammatory cytokine pathogenic in psoriasis. It considers an influential factor in controlling moderate to severe psoriasis. This study aimed to evaluate the impact of Adalimumab on COVID-19 incidence in patients with psoriasis. Methods: This cross-sectional study was performed at Baqiyatallah Hospital in 2021. Eighty patients with psoriasis referred to Baqiyatallah Hospital were included in the study. Patients were divided into two groups, one group was treated with Adalimumab, and the other group received the control treatment. The incidence of the disease was assessed by the history of COVID-19 signs and symptoms, positive RT‐ PCR testing and graphing, and physician diagnosis. Findings: The mean age of patients was 39.5 (±7.9 S.D.). 36(45%) patients were infected with COVID-19, and 44 (55%) patients were not infected, and there was no significant difference between the two groups in the infection with COVID-19 (P value = 0.36). There was a significant relationship between infection with COVID-19 and the severity of psoriasis (P value=0.01).  Although, in the severe psoriasis group, which was significantly more affected byCOVID-19, there was no statistically significant relationship between Adalimumab consumption and COVID-19 affection (P value = 0.19). Conclusion: Psoriasis patients treated  with Adalimumab are as prone to COVID-19 infection. However, patients with severe psoriasis are more likely to develop COVID-19; this matter is not related to the use of Adalimumab, and it is not necessary to discontinue or change Adalimumab.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Premedication drugs’ evaluation and incidence of infusion-related reactions in patients receiving amphotericin B

Background: Amphotericin B is one of the most useful therapeutic modalities for the treatment of patients with invasive fungal infections, in spite of serious side effects, namely kidney injury, electrolyte imbalances, and infusion-related reactions. The goal of this study was to assess the different aspects of premedication practice and the incidence and types of infusion-related reactions in ...

full text

Association of Physical Activity level with the COVID-19 Incidence in Patients with Type 2 Diabetes

Background and Objective: Type 2 Diabetes Mellitus (T2DM) is among the epidemic metabolic chronic diseases that attenuates physiological functions, including hematopoiesis and immune responses, developing a higher risk of COVID-19 incidence. This study purposed to study the association of physical activity level (PAL) with the COVID-19 incidence in patients with T2DM. Materials and Methods: Al...

full text

Incidence of Cardiac Dysrhythmia in COVID-19 Patients Treated with Conventional Medications – A Brief Report of 58 Patients

Introduction: When World Health Organization (WHO) declared that Covid-19 is a pandemic, a wide range of drugs, including antiviral drugs and antibiotics have been taken to treat this disease. This study aimed to evaluate the incidence of cardiac dysrhythmias due to the conventional medications in 58 COVID -19 patients. Methods: This study is a cross-sectional analytical study was performed to...

full text

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study

OBJECTIVES The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. METHODS A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation rate (ESR), C-...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue 3

pages  7- 7

publication date 2023-06

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023